Lilly to Participate in Citi's 17th Annual BioPharma Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
It's Good to Be Eli Lilly (LLY) in 2022 Says Citi Analyst
August 25, 2022 3:18 PM EDTEli Lilly & Co. (NYSE: LLY) price target was raised to $370 from $285, with its Buy rating maintained at Citi on Thursday.
Analyst Andrew Baum stated in his research note that "it's good to be Lilly in 2022."
"We have increased our peak risk-adjusted tirzepatide... More
